Assay development for point-of-care COVID-19 antibody detection
A key requirement for returning to societal and economic normality is the evaluation and surveillanceof SARS-CoV-2 infection and immunity. The proposed technologies described herein, enable a safe and effectivediagnostic test that can quickly provide an easily interpreted result for SARS-CoV-2 immunity, all without complicated equipment, expensive reagents, or high-level biosafety containment facilities. Such a system would allow for rapid testing in decentralized labs or at point-of-care providing quick data information on antibody responses produced by infection or vaccination. This data will be invaluable for assessing the most efficacious SARS-CoV-2 vaccine(s) for use in population-wide vaccination booster campaigns against currently circulating strains, and will also guide future public health mitigation strategies to reduce the spread of viral transmission.
Voir la description complète du projetDustin Little;Marc Adler
OxiLight
Life Sciences
Professional, scientific and technical services
Toronto Metropolitan University
Accelerate
